| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CYP-M |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human CYP20A1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CYP20A1抗体的虚构参考文献示例(实际文献需通过学术数据库验证)：
1. **文献名称**: "Development and Validation of a Polyclonal Antibody for Human CYP20A1 Protein Detection"
**作者**: Zhang, L. et al.
**摘要**: 本研究报道了一种针对人CYP20A1蛋白的多克隆抗体的开发，通过免疫印迹(Western blot)和免疫组化验证其特异性，确认其在脑组织和肝脏样本中的表达模式。
2. **文献名称**: "CYP20A1 Expression Profiling in Neurodegenerative Disorders Using a Novel Monoclonal Antibody"
**作者**: Tanaka, K. et al.
**摘要**: 利用新型单克隆抗体分析CYP20A1在阿尔茨海默病和帕金森病患者脑组织中的表达水平，发现其与疾病进展相关的潜在生物标志物作用。
3. **文献名称**: "Functional Characterization of CYP20A1 in Cellular Redox Homeostasis"
**作者**: Müller, R. et al.
**摘要**: 通过特异性抗体抑制CYP20A1蛋白，研究其在氧化应激反应中的功能，揭示其对细胞活性氧(ROS)调控的分子机制。
4. **文献名称**: "Comparative Analysis of CYP20A1 Antibody Cross-Reactivity Across Species"
**作者**: Gupta, S. et al.
**摘要**: 评估不同物种(人、小鼠、大鼠)中CYP20A1抗体的交叉反应性，为跨物种研究提供实验依据，并验证抗体在临床前模型中的应用潜力。
**提示**：以上为模拟示例，建议通过PubMed、Google Scholar等平台检索真实文献(关键词：CYP20A1 antibody, cytochrome P450 20A1)。
The CYP20A1 antibody targets the cytochrome P450 family 20 subfamily A member 1 (CYP20A1), a poorly characterized enzyme within the cytochrome P450 superfamily. Unlike many CYP enzymes involved in drug metabolism or xenobiotic detoxification, CYP20A1’s physiological substrates and precise biological functions remain unclear. It is expressed in various tissues, including the brain, liver, and kidneys, suggesting potential roles in endogenous metabolic pathways. Structural studies indicate it may possess atypical catalytic features compared to other CYPs, possibly linked to cholesterol or neurosteroid metabolism.
CYP20A1 antibodies are primarily used in research to study its expression patterns, subcellular localization (notably endoplasmic reticulum association), and regulatory mechanisms. Emerging evidence implicates CYP20A1 in neurological disorders, such as Parkinson’s disease, and cancer progression, though mechanistic insights are limited. Some studies report elevated CYP20A1 levels in gliomas or colorectal cancers, hinting at its potential as a diagnostic or prognostic marker. However, inconsistent expression data across studies underscore the need for further validation.
Commercial CYP20A1 antibodies are typically developed against specific epitopes, often validated via Western blotting, immunohistochemistry, or immunofluorescence. Researchers must verify antibody specificity due to homology with other CYPs and the protein’s low abundance. Current investigations focus on clarifying its enzymatic activity, interaction networks, and disease relevance, positioning CYP20A1 as a molecule of growing interest in metabolic and oncological research.
×
